Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

915 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, Berdel WE, Büchner T, Wörmann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C, Bohlander SK. Metzeler KH, et al. Among authors: hiddemann w. J Clin Oncol. 2009 Oct 20;27(30):5031-8. doi: 10.1200/JCO.2008.20.5328. Epub 2009 Sep 14. J Clin Oncol. 2009. PMID: 19752345
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: hiddemann w. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: hiddemann w. J Clin Oncol. 2006 Jun 1;24(16):2480-9. doi: 10.1200/JCO.2005.04.5013. J Clin Oncol. 2006. PMID: 16735702 Clinical Trial.
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C; Cancer and Leukemia Group B; German AML Cooperative Group. Metzeler KH, et al. Among authors: hiddemann w. Blood. 2008 Nov 15;112(10):4193-201. doi: 10.1182/blood-2008-02-134411. Epub 2008 Aug 20. Blood. 2008. PMID: 18716133 Free PMC article. Clinical Trial.
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: hiddemann w. J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047294 Clinical Trial.
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K. Reindl C, et al. Among authors: hiddemann w. Clin Cancer Res. 2009 Apr 1;15(7):2238-47. doi: 10.1158/1078-0432.CCR-08-1325. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276253
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K. Dufour A, et al. Among authors: hiddemann w. J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038735
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group. Dufour A, et al. Among authors: hiddemann w. Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24. Ann Hematol. 2012. PMID: 22362118
915 results